Restless Legs Syndrome: Challenges to Treatment.
Study Design
- نوع الدراسة
- Review
- المجتمع المدروس
- None
- التدخل
- Restless Legs Syndrome: Challenges to Treatment. None
- المقارن
- None
- النتيجة الأولية
- None
- اتجاه التأثير
- Positive
- خطر التحيز
- Unclear
Abstract
For a long time, dopaminergic treatment (DT) was the medication for restless legs syndrome. Although DT is effective and safe over the short-term, complications develop over longer periods, including augmentation, tolerance, and impulse control disorders. Nowadays, it is recommended that first-line treatment should be alpha-2 ligands, which are more effective in the absence of previous DT. As a second-line treatment, opioids, such as oxycodone extended-release with naloxone, are approved in Europe. Brain iron should be monitored before and during treatment and corrected if necessary. Two new promising non-DTs are being developed: perampanel and dipyridamole. More research is needed.
باختصار
First-line treatment for restless legs syndrome should be alpha-2 ligands, which are more effective in the absence of previous DT, and opioids, such as oxycodone extended-release with naloxone, are approved in Europe.
Used In Evidence Reviews
Similar Papers
Sleep medicine · 2004
Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).
Neurology · 2004
Restless legs syndrome and pregnancy.
Movement disorders : official journal of the Movement Disorder Society · 2008
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.
Nature reviews. Neurology · 2010
Restless legs syndrome: pathophysiology, clinical presentation and management.
Sleep medicine · 2014
Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
Sleep medicine · 2016